019175.KS KSC
Shinpoong Pharmaceutical Co.,Ltd
1W: +1.7%
1M: -10.3%
3M: +5.5%
YTD: -29.9%
1Y: -44.1%
3Y: -47.7%
5Y: -89.7%
₩14,080.00 ($10.47)
-70.00 (-0.49%)
Weekly Expected Move ±5.5%
₩12518
₩13299
₩14080
₩14861
₩15642
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
$17.3B
+213.8% ▲
5Y CAGR: -3.0%
Capital Expenditures
$3.5B
+42.9% ▲
5Y CAGR: +2.2%
Free Cash Flow
$13.8B
+164.8% ▲
5Y CAGR: -4.1%
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$5.4B
+400.2% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$11.5B | -$35.3B | -$57.3B | -$15.4B | $8.8B |
| Depreciation & Amort. | $12.7B | $12.8B | $11.9B | $12.0B | $11.4B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$9.7B | -$12.5B | $351M | -$9.8B | -$10.1B |
| Other Non-Cash Items | -$62.4B | $8.6B | $20.2B | -$1.9B | $7.1B |
| Operating Cash Flow | -$71.0B | -$26.4B | -$24.8B | -$15.2B | $17.3B |
| — Investing Activities — | |||||
| Capital Expenditures | -$5.6B | -$6.2B | -$14.9B | -$5.6B | -$4.0B |
| Acquisitions (Net) | -$5.3B | $1M | $0 | $0 | $373K |
| Investment Purchases | -$228.4B | -$64.5B | -$3.0B | -$64.8B | -$121.7B |
| Investment Sales | $288.1B | $113.4B | $1.8B | $67.3B | $111.0B |
| Other Investing | $264M | $575M | -$239M | $8.6B | $5M |
| Investing Cash Flow | $49.0B | $43.2B | -$16.3B | $5.6B | -$14.7B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$1.3B | -$268M | $45.0B | $7.5B | $5.1B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$5.2B | $0 | $0 | $0 | $0 |
| Other Financing | $0 | -$1.6B | -$1.8B | -$1.3B | -$1.4B |
| Financing Cash Flow | -$6.4B | -$1.9B | $43.2B | $6.2B | $3.7B |
| Net Change in Cash | -$28.2B | $14.1B | $2.1B | -$1.8B | $5.4B |
| Cash End of Period | $27.6B | $41.7B | $43.8B | $42.0B | $47.4B |
| Free Cash Flow | -$76.6B | -$32.7B | -$39.9B | -$21.2B | $13.8B |